Morgan Stanley resumed coverage on Denali Therapeutics with a new price target

3/7/25 8:22:55 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Morgan Stanley resumed coverage of Denali Therapeutics with a rating of Overweight and set a new price target of $33.00 from $41.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$DNLI

Date	Price Target	Rating	Analyst
4/10/2025		Neutral → Overweight	Cantor Fitzgerald
3/7/2025	$41.00 → $33.00	Overweight	Morgan Stanley
2/11/2025	$31.00	Buy	Deutsche Bank
1/7/2025	$31.00	Outperform	Robert W. Baird
1/3/2025		Outperform	William Blair
12/16/2024	$37.00	Hold → Buy	Stifel
10/10/2024		Mkt Perform	Raymond James
10/7/2024		Overweight → Neutral	Cantor Fitzgerald